Accueil > Actualité > Société

J&J: positive data for lung cancer drug

( - Johnson & Johnson's Janssen Pharmaceutical Companies yesterday announced long-term results from a study of the combination of Rybrevant (amivantamab-vmjw) and lazertinib as first-line treatment for patients with EGFR-mutated non-small cell lung cancer (NSCLC).

These results and additional data were presented at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting.

The estimated progression-free survival rate was 85% at one year, 65% at two years and 51% at three years. The longest duration of ongoing treatment was more than three years (37.2 months) and the longest median duration of response was nearly three years (35.7 months).

Copyright (c) 2023 All rights reserved.





A quel niveau sera le CAC40 à fin décembre 2023:

En hausse à 7650Pts
En hausse à 7480Pts
Stable sur le niveau des 7230Pts
En baisse à 7100Pts
En baisse à 6850Pts
Qui sommes-nous ? | Nous contacter | FAQ | Mentions légales | RSS | © Copyright 2007 Cercle Finance. Tous droits réservés.